{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:47:17Z","timestamp":1791308837817,"version":"4.3.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ijantimicag.2008.05.023","type":"journal-article","created":{"date-parts":[[2008,9,14]],"date-time":"2008-09-14T09:56:13Z","timestamp":1221386173000},"page":"511-514","source":"Crossref","is-referenced-by-count":33,"title":["Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies"],"prefix":"10.1016","volume":"32","author":[{"given":"Elizabeth","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Espinel-Ingroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Troke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2008.05.023_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1010954803886","article-title":"In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature","volume":"150","author":"Espinel-Ingroff","year":"2001","journal-title":"Mycopathologia"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/JCM.40.3.852-856.2002","article-title":"Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program 1997 to 2000","volume":"40","author":"Pfaller","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1128\/JCM.41.1.78-83.2003","article-title":"In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood","volume":"41","author":"Pfaller","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.diagmicrobio.2003.09.009","article-title":"In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents","volume":"48","author":"Pfaller","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2003.09.008","article-title":"In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program","volume":"48","author":"Pfaller","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib6","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1128\/JCM.43.12.5848-5859.2005","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1128\/JCM.44.3.819-826.2006","article-title":"Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints","volume":"44","author":"Pfaller","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0732-8893(03)00086-5","article-title":"Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996\u20132001)","volume":"46","author":"Marco","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib9","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib10","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ajo.2003.11.078","article-title":"In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens","volume":"137","author":"Marangon","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijantimicag.2004.01.014","article-title":"In vitro activity of voriconazole against Candida species isolated in Taiwan","volume":"24","author":"Yang","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijantimicag.2005.06.005","article-title":"Voriconazole activity against clinical yeast isolates: a multicentre Italian study","volume":"26","author":"Morace","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jac\/dkh532","article-title":"Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital","volume":"55","author":"Munoz","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib14","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1128\/JCM.44.5.1912-1914.2006","article-title":"Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns","volume":"44","author":"Peman","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib15","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important moulds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib16","first-page":"2227","article-title":"Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS","volume":"12","author":"Hegener-P","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib17","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/322653","article-title":"A randomized, double-blind, double-dummy, multicentre trial of voriconazole and fluconazole in the treatment of oesophageal candidiasis in immunocompromised patients","volume":"33","author":"Ally","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib18","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib19","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jinf.2004.08.032","article-title":"Emergence of Candida albicans fungemia during voriconazole therapy","volume":"51","author":"Mohammedi","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1592\/phco.2005.25.6.893","article-title":"Intravenous voriconazole therapy in a preterm infant","volume":"25","author":"Muldrew","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib21","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JCM.44.5.1740-1743.2006","article-title":"Clinical significance of azole antifungal drug cross-resistance in Candida glabrata","volume":"44","author":"Panackal","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib22","unstructured":"Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. 2nd ed. Approved standard. M27-A2. Villanova, PA: CLSI; 2002."},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/AAC.41.3.575","article-title":"In vitro activities of voriconazole (UK-109 496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection","volume":"41","author":"Ruhnke","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1086\/342384","article-title":"Has antifungal susceptibility testing come of age?","volume":"35","author":"Rex","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/46.2.338","article-title":"Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis","volume":"46","author":"Muller","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.49.2.668-679.2005","article-title":"Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance","volume":"49","author":"Sanguinetti","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/JCM.01551-06","article-title":"Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods","volume":"45","author":"Pfaller","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib29","first-page":"21","article-title":"In vitro activity of voriconazole against yeast and algae isolates according to new resistance pattern cut-off points","volume":"19","author":"Pem\u00e1n","year":"2006","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0732-8893(03)00094-4","article-title":"Colony morphology switching of Candida lusitaniae and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature","volume":"47","author":"Favel","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.05.023_bib31","first-page":"523","article-title":"Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004","volume":"54","author":"Eloy","year":"2006","journal-title":"Pathol Biol (Paris)"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857908003063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857908003063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:39:17Z","timestamp":1557794357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857908003063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0924857908003063"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.05.023","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}